Novartis’s Beovu Launch Clouded By Safety Worries
Beovu Uncertainty Should Benefit Regeneron’s Eylea
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.
You may also be interested in...
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.